Consumer-health group selling infant formula/probiotics (Biostime), vitamins (Swisse) and pet nutrition (Solid Gold) globally.
Consumer-health group selling infant formula/probiotics (Biostime), vitamins (Swisse) and pet nutrition (Solid Gold) globally.
Grew by buying brands: Swisse was bought in 2015, and Solid Gold and Zesty Paws added pet nutrition later. Swisse sells in Australia and China; China remains the largest market, much of it through online platforms, including cross-border channels.
In one line: A Chinese/Australian Reckitt-style baby & wellness nutrition group.
Moat: narrow (brand, distribution). Strong Swisse/Biostime brand recognition and cross-border e-commerce distribution in China.
Headquarters: Guangzhou, China / Australia · Founded: 1999 · Employees: 2,758
Size Health and Happiness (H&H) International (1112.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $2.15B, the 392nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$26.32 on 18 Nov 2026.
Performance Over six months the shares gained 108.2%, against -3.5% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 24.3% over the last twelve months (peer median +8.3%); the operating margin is 15.6% (peer median 15.8%).
Valuation It trades at 13.2× forward earnings against a peer median of 17.0× (7th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.9 points above its cost of capital (9.6% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$17.9B | HK$15.6B | HK$14.2B | HK$15.4B | HK$14.9B |
| Revenue growth | — | +10% | -8% | +4% | — |
| Gross profit | HK$11.5B | HK$9.72B | HK$8.58B | HK$9.17B | HK$8.96B |
| EBITDA | HK$3.14B | HK$2.15B | HK$1.75B | HK$2.15B | HK$2.17B |
| Net income | HK$833M | HK$213M | -HK$58.2M | HK$643M | HK$711M |
| Free cash flow | HK$1.86B | HK$1.05B | HK$644M | HK$342M | HK$1.13B |
| Capital expenditure | HK$103M | HK$102M | HK$106M | HK$101M | HK$119M |
| Total debt | n/a | HK$10.1B | HK$9.96B | HK$10.2B | HK$10.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Health and Happiness (H&H) International 1112.HK | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% |
| Reckitt Benckiser RKT.L | $47.5B | +22% | -2% | 28% | 16.7× | 2.1% |
| Nestle NESN.SW | $258B | +8% | -2% | 16% | 19.1× | 1.3% |
| Danone BN.PA | $48.7B | +13% | 0% | 15% | 17.5× | -0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1112.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +24.6% | -1.3% | 2nd highest of 21 |
| 6-month return | +108.2% | -3.5% | highest of 21 |
| Distance from 52-week high | -1.9% | -26.3% | 3rd highest of 21 |
| Revenue growth (TTM) | +24.3% | +8.3% | 6th highest of 21 |
| Operating margin | 15.6% | 15.8% | 11th highest of 21 |
| Forward P/E | 13.2× | 17.0× | 7th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -1.7% | 2.1% | 8th least demanding of 20 |
| Growth delivered (Del g) | +4.4% | +5.9% | 7th lowest of 20 |
| Hurdle (Req g minus delivered) | -6.0 pp | -8.3 pp | 9th most demanding of 20 |
| ROIC minus cost of capital | +6.9 pp | +2.7 pp | 8th highest of 21 |
| EV / EBITDA | 7.5× | 17.3× | 2nd cheapest of 10 |
| Net debt / EBITDA | 2.1× | -0.3× | 4th most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% | +4.4% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% | +11.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% | +5.3% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| By-health 300146.SZ | China | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% | +0.6% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $2.97B | -7% | -4% | -13% | n/a | 5.0% | +1.0% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.00B | +11% | -14% | 9% | 91.7× | 33.8% | +5.9% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Bausch Health Companies BHC.TO | Canada | $3.27B | +66% | +10% | 27% | 2.0× | -14.8% | +5.9% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $3.83B | -7% | +32% | 21% | 17.5× | -3.9% | -2.2% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |